Future Oncology · 2014 · 10 citations · 36 references
PharmacyOncologyPharmacotherapyEndocrine OncologyEndocrine PharmacotherapyOncology PharmacotherapyBreast Cancer PharmacotherapyHormonal Cancer TherapyHormonal TherapyMetastatic Breast CancerBreast Cancer Endocrine TherapyBreast Cancer Hormonal TherapyCombination Endocrine TherapyHormone Receptor - Positive Breast CancerHormone Receptor-positive DiseaseMultikinase InhibitorsSorafenib TherapyTumor Cell Survival Pathways
BACKGROUND: Targeting growth factor and survival pathways may delay endocrine-resistance in estrogen receptor-positive breast cancer. MATERIALS & METHODS: A pilot Phase II study adding sorafenib to endocrine therapy in 11 patients with metastatic estrogen receptor-positive breast cancer was conducted. Primary end point was response by RECIST after 3 months of sorafenib. Secondary end points included safety, time to progression and biomarker modulation. The study closed early owing to slow accrual. RESULTS: Eight out of 11 patients had progressive disease on study entry and three had stable disease. Of the ten evaluable patients, seven experienced stable disease (70%) and three experienced progressive diseas (30%), with a median time to progression of 6.1 months (8.4 months in the seven patients on tamoxifen). The serum samples demonstrated a significant reduction in VEGF receptor 2 and PDGF receptor-α. Microarray analysis identified 32 suppressed genes, no induced genes and 29 enriched Kyoto Encyclopedia of Genes and Genomes pathways. CONCLUSION: The strategy of adding a targeted agent to endocrine therapy upon resistance may be worthwhile testing in larger studies.
36
KEGG for integration and interpretation of large-scale molecular data sets
Minoru Kanehisa, Susumu Goto, Yoko Sato et al. · Nucleic Acids Research · 2011 · 5K citations · Full text
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Dorit Shweiki, Ahuva Itin, Dov Soffer et al. · Nature · 1992 · 4.6K citations